Results 271 to 280 of about 308,099 (338)

Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study. [PDF]

Front Immunol
Hu L, Wan S, Song X.
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Challenges and Perspectives in Treating Individuals With Musculoskeletal Disorders and Comorbidity: A Systematic Literature Review With a Descriptive Thematic Synthesis. [PDF]

Scand J Caring Sci
Rømer LC, Gandløse JS, Andreasen J, Skou ST, Palsson TS.   +4 more
europepmc   +1 more source

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran, Mohammad Ali Omrani, Flory T. Muanda   +2 more
wiley   +1 more source

Persistent musculoskeletal pain and its association with future mental distress in adolescents: The Fit Futures study. [PDF]

BMC Public Health
Smedbråten K, Riiser K, Andersen M, Øiestad BE.   +3 more
europepmc   +1 more source

The study of marketing opportunities for the use of the raw material of feverfew (Tanacetum parthenium L.) in the pharmacotherapy of musculoskeletal system diseases

О.М. Yevtushenko, О. А. Рубан, Mariia Velia, І. V. Kovalevska   +3 more
openalex   +2 more sources

Optimizing biophysical properties of cellular niches to enhance stem cell‐derived extracellular vesicle function in musculoskeletal regeneration

BMEMat, EarlyView.
Extracellular vesicles (EVs) derived from stem cells show promise for applications in regenerative medicine, but their scalability and yield remain challenges. This review explores the approaches for biophysical modulations within cell niches on EV properties, discusses the current clinical application of EVs, and provides an outlook on the existing ...
Yang Xu, Chung Yin Matthew Cheung, Liling Liu, Hoi Pan Harry Cheung, Kam Yu Tam, Dai Fei Elmer Ker, Sarah H. Cartmell, Chuanbin Mao, Zhiyong Zhang, Dan Michelle Wang   +9 more
wiley   +1 more source

Mesenchymal stem cell-derived extracellular matrix for musculoskeletal tissue regeneration. [PDF]

Commun Biol
Lv S, Wang J, Chen J, Yu Y, Huang X, Zhao G, Zhou X, Xu Y.   +7 more
europepmc   +1 more source